Novo Nordisk's sales rocket in 2022
Danish diabetes care giant Novo Nordisk (NOV: N) today reported that sales for full-year 2022 increased by 26% in Danish kroner and by 16% at constant exchange rates to 177.0 billion kroner ($25.6 billion) in 2022, slightly ahead of analysts’ expectations of 176 billion kroner.
Net profit rose 16% as reported to 55.5 billion kroner, compared to analysts’ expectations of 55.13 billion, according to a survey by Factset. Operating profit increased 28% to 74.8 billion kroner and diluted earnings per share were up 18% at 24.44 kroner.
For the 2023 outlook, Novo Nordisk says both sales and operating profit growth are expected to be 13%-19% at constant exchange rates (CER). Sales and operating profit growth reported in Danish kroner are expected to be 4 and 5 percentage points lower than at CER, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze